Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes

Glycoconjugate Journal

Volumn 33, Issue 4, 2016, Pages 527-535

  Fokkens, Bernardina T ^a,b   Smit, Andries J ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Advanced glycation endproducts; Diabetes complications; Diabetes mellitus; Skin autofluorescence; Skin intrinsic fluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C;

ARTICLE; CARBOHYDRATE METABOLISM; CEREBROVASCULAR DISEASE; CORONARY ARTERY CALCIFICATION; DECISION TREE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FLUORESCENCE ANALYSIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIGHT ABSORPTION; LIGHT SCATTERING; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SKIN COLOR; SKIN FLUORESCENCE; SKIN PIGMENTATION; VALIDATION PROCESS; VASCULAR DISEASE; DIABETIC COMPLICATION; FLUORESCENCE; METABOLISM; SKIN;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FLUORESCENCE; GLYCATION END PRODUCTS, ADVANCED; HUMANS; SKIN;

EID: 84973661021     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-016-9683-1     Document Type: Article

References (88)

1. Winer N., Sowers J.R.: Epidemiology of diabetes. J. Clin. Pharmacol. 44, 397–405 (2004)
2. Brownlee M.: Negative consequences of glycation. Metabolism. 49, 9–13 (2000)
3. Semba R.D., Nicklett E.J., Ferrucci L.: Does accumulation of advanced glycation end products contribute to the aging phenotype? J. Gerontol. A Biol. Sci. Med. Sci. 65, 963–975 (2010)
4. Stinghen A.E., Massy Z.A., Vlassara H., Striker G.E., Boullier A.: Uremic toxicity of advanced glycation end products in CKD. J. Am. Soc. Nephrol. 27, 354–370 (2015)
5. Monnier V.M., Vishwanath V., Frank K.E., Elmets C.A., Dauchot P., Kohn R.R.: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N. Engl. J. Med. 314, 403–408 (1986)
6. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., Sivitz W., Monnier V.M.: DCCT skin collagen ancillary study group: glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 54, 3103–3111 (2005)
7. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.: 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008)
8. Meerwaldt R., Graaff R., Oomen P.H., Links T.P., Jager J.J., Alderson N.L., Thorpe S.R., Baynes J.W., Gans R.O., Smit A.J.: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 47, 1324–1330 (2004)
9. Shipanova I.N., Glomb M.A., Nagaraj R.H.: Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. Biochem. Biophys. 344, 29–36 (1997)
10. Nakamura K., Nakazawa Y., Ienaga K.: Acid-stable fluorescent advanced glycation end products: vesperlysines a, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose. Biochem. Biophys. Res. Commun. 232, 227–230 (1997)
11. Pongor S., Ulrich P.C., Bencsath F.A., Cerami A.: Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc. Natl. Acad. Sci. U. S. A. 81, 2684–2688 (1984)
12. Sell D.R., Monnier V.M.: Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J. Biol. Chem. 264, 21597–21602 (1989)
13. Koetsier M., Lutgers H., Smit A.J., Links T.P., Vries R.D., Gans R.O., Rakhorst G., Graaff R.: Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient. Opt. Express. 17, 509–519 (2009)
14. Conway B., Edmundowicz D., Matter N., Maynard J., Orchard T.: Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol. Ther. 12, 339–345 (2010)
15. den Hollander N.C., Mulder D.J., Graaff R., Thorpe S.R., Baynes J.W., Smit G.P., Smit A.J.: Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia. J. Inherit. Metab. Dis. 30, 916–923 (2007)
16. Meerwaldt R., Hartog J.W., Graaff R., Huisman R.J., Links T.P., den Hollander N.C., Thorpe S.R., Baynes J.W., Navis G., Gans R.O., Smit A.J.: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol. 16, 3687–3693 (2005)
17. Smit A.J., Gerrits E.G.: Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 19, 527–533 (2010)
18. Hull E., Ediger M., Unione A., Deemer E., Stroman M., Baynes J.: Noninvasive, optical detection of diabetes: model studies with porcine skin. Opt. Express. 12, 4496–4510 (2004)
19. Ediger, M.N., Fleming, C.M., Rohrscheib, M., Way, J.F., Nguyen, C.M., Maynard, J.D.: Noninvasive fluorescence spectroscopy for diabetes screening: a clinical case-control study. Abstract presented at the Diabetes Technology Meeting, 11 November 2005, San Francisco, California
20. Sachdeva S.: Fitzpatrick skin typing: applications in dermatology. Indian J. Dermatol. Venereol. Leprol. 75, 93–96 (2009)
21. Koetsier M., Lutgers H.L., de Jonge C., Links T.P., Smit A.J., Graaff R.: Reference values of skin autofluorescence. Diabetes Technol. Ther. 12, 399–403 (2010)
22. Koetsier M., Nur E., Chunmao H., Lutgers H.L., Links T.P., Smit A.J., Rakhorst G., Graaff R.: Skin color independent assessment of aging using skin autofluorescence. Opt. Express. 18, 14416–14429 (2010)
23. Noordzij M.J., Lefrandt J.D., Graaff R., Smit A.J.: Dermal factors influencing measurement of skin autofluorescence. Diabetes Technol. Ther. 13, 165–170 (2011)
24. Stirban A., Nandrean S., Negrean M., Koschinsky T., Tschoepe D.: Skin autofluorescence increases postprandially in human subjects. Diabetes Technol. Ther. 10, 200–205 (2008)
25. Mulder D.J., Water T.V., Lutgers H.L., Graaff R., Gans R.O., Zijlstra F., Smit A.J.: Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol. Ther. 8, 523–535 (2006)
26. Gerrits E.G., Smit A.J., Bilo H.J.: AGEs, autofluorescence and renal function. Nephrol. Dial. Transplant. 24, 710–713 (2009)
27. Lutgers H.L., Graaff R., Links T.P., Ubink-Veltmaat L.J., Bilo H.J., Gans R.O., Smit A.J.: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 29, 2654–2659 (2006)
28. van Waateringe R.P., Slagter S.N., van der Klauw M.M., van Vliet-Ostaptchouk J.V., Graaff R., Paterson A.D., Lutgers H.L., Wolffenbuttel B.H.: Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study. Eur. J. Clin. Investig. 46, 481–490 (2016)
29. Olson B.P., Matter N.I., Ediger M.N., Hull E.L., Maynard J.D.: Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance. J. Diabetes Sci. Technol. 7, 990–1000 (2013)
30. Cleary P.A., Braffett B.H., Orchard T., Lyons T.J., Maynard J., Cowie C., Gubitosi-Klug R.A., Way J., Anderson K., Barnie A., Villavicencio S.: DCCT/EDIC research group: clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Technol. Ther. 15, 466–474 (2013)
31. Eny K.M., Orchard T.J., Miller R.G., Maynard J., Grant D.M., Costacou T., Cleary P.A., Braffett B.H., Paterson A.D.: DCCT/EDIC research group: caffeine consumption contributes to skin intrinsic fluorescence in type 1 diabetes. Diabetes Technol. Ther. 17, 726–734 (2015)
32. Stirban A.: Noninvasive skin fluorescence spectroscopy for diabetes screening. J. Diabetes Sci. Technol. 7, 1001–1004 (2013)
33. Smit A.J., Smit J.M., Botterblom G.J., Mulder D.J.: Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. PLoS One. 8, e65592 (2013)
34. Maynard J.D., Rohrscheib M., Way J.F., Nguyen C.M., Ediger M.N.: Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care. 30, 1120–1124 (2007)
35. Tentolouris N., Lathouris P., Lontou S., Tzemos K., Maynard J.: Screening for HbA1c-defined prediabetes and diabetes in an at-risk greek population: performance comparison of random capillary glucose, the ADA diabetes risk test and skin fluorescence spectroscopy. Diabetes Res. Clin. Pract. 100, 39–45 (2013)
36. Gopal P., Reynaert N.L., Scheijen J.L., Engelen L., Schalkwijk C.G., Franssen F.M., Wouters E.F., Rutten E.P.: Plasma AGEs and skin autofluorescence are increased in COPD. Eur. Respir. J. 43, 430–438 (2013)
37. Tanaka K., Katoh T., Asai J., Nemoto F., Suzuki H., Asahi K., Sato K., Sakaue M., Miyata T., Watanabe T.: Relationship of skin autofluorescence to cardiovascular disease in Japanese hemodialysis patients. Ther. Apher. Dial. 14, 334–340 (2010)
38. Hartog J.W., Hummel Y.M., Voors A.A., Schalkwijk C.G., Miyata T., Huisman R.M., Smit A.J., Van Veldhuisen D.J.: Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J. Card. Fail. 14, 596–602 (2008)
39. Verzijl N., DeGroot J., Thorpe S.R., Bank R.A., Shaw J.N., Lyons T.J., Bijlsma J.W., Lafeber F.P., Baynes J.W., TeKoppele J.M.: Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 275, 39027–39031 (2000)
40. Noordzij M.J., Lefrandt J.D., Graaff R., Smit A.J.: Skin autofluorescence and glycemic variability. Diabetes Technol. Ther. 12, 581–585 (2010)
41. Gerrits E.G., Lutgers H.L., Kleefstra N., Groenier K.H., Smit A.J., Gans R.O., Bilo H.J.: Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9). J. Diabetes Sci. Technol. 2, 572–577 (2008)
42. Sugisawa E., Miura J., Iwamoto Y., Uchigata Y.: Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. Diabetes Care. 36, 2339–2345 (2013)
43. Januszewski A.S., Sachithanandan N., Karschimkus C., O'Neal D.N., Yeung C.K., Alkatib N., Jenkins A.J.: Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet. Med. 29, 726–733 (2012)
44. Hofmann B., Jacobs K., Navarrete Santos A., Wienke A., Silber R.E., Simm A.: Relationship between cardiac tissue glycation and skin autofluorescence in patients with coronary artery disease. Diabete Metab. 41, 410–415 (2015)
45. Bos D.C., de Ranitz-Greven W.L., de Valk H.W.: Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Diabetes Technol. Ther. 13, 773–779 (2011)
46. Chabroux S., Canoui-Poitrine F., Reffet S., Mills-Joncour G., Morelon E., Colin C., Thivolet C.: Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabete Metab. 36, 152–157 (2010)
47. Meerwaldt R., Links T.P., Graaff R., Hoogenberg K., Lefrandt J.D., Baynes J.W., Gans R.O., Smit A.J.: Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia. 48, 1637–1644 (2005)
48. Monami M., Lamanna C., Gori F., Bartalucci F., Marchionni N., Mannucci E.: Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Res. Clin. Pract. 79, 56–60 (2008)
49. Gerrits E.G., Lutgers H.L., Kleefstra N., Graaff R., Groenier K.H., Smit A.J., Gans R.O., Bilo H.J.: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 31, 517–521 (2008)
50. Lutgers H.L., Gerrits E.G., Graaff R., Links T.P., Sluiter W.J., Gans R.O., Bilo H.J., Smit A.J.: Skin autofluorescence provides additional information to the UK prospective diabetes study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 52, 789–797 (2009)
51. Meerwaldt R., Lutgers H.L., Links T.P., Graaff R., Baynes J.W., Gans R.O., Smit A.J.: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care. 30, 107–112 (2007)
52. Ahdi M., Gerdes V.E., Graaff R., Kuipers S., Smit A.J., Meesters E.W.: Skin autofluorescence and complications of diabetes: does ethnic background or skin color matter? Diabetes Technol. Ther. 17, 88–95 (2015)
53. Liu C., Xu L., Gao H., Ye J., Huang Y., Wu M., Xie T., Ni P., Yu X., Cao Y., Lu S.: The association between skin autofluorescence and vascular complications in Chinese patients with diabetic foot ulcer: an observational study done in shanghai. Int. J. Low Extrem Wounds. 14, 28–36 (2015)
54. Noordzij M.J., Mulder D.J., Oomen P.H., Brouwer T., Jager J., Castro Cabezas M., Lefrandt J.D., Smit A.J.: Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus-a multi-Centre study. Diabet. Med. 29, 1556–1561 (2012)
55. Tanaka K., Tani Y., Asai J., Nemoto F., Kusano Y., Suzuki H., Hayashi Y., Asahi K., Nakayama M., Miyata T., Watanabe T.: Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes. Diabet. Med. 29, 492–500 (2012)
56. Yasuda M., Shimura M., Kunikata H., Kanazawa H., Yasuda K., Tanaka Y., Konno H., Takahashi M., Kokubun T., Maruyama K., Sato N., Kakizaki M., Sato M., Tsuji I., Miyata T., Nakazawa T.: Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes. Curr. Eye Res. 40, 338–345 (2015)
57. Hirano T., Iesato Y., Toriyama Y., Imai A., Chiba D., Murata T.: Correlation between diabetic retinopathy severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients. J. Diabetes Complicat. 28, 729–734 (2014)
58. Araszkiewicz A., Naskret D., Niedzwiecki P., Samborski P., Wierusz-Wysocka B., Zozulinska-Ziolkiewicz D.: Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes. Diabetes Technol. Ther. 13, 837–842 (2011)
59. Araszkiewicz A., Naskret D., Zozulinska-Ziolkiewicz D., Pilacinski S., Uruska A., Grzelka A., Wegner M., Wierusz-Wysocka B.: Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study. Microvasc. Res. 98, 62–67 (2015)
60. Genevieve M., Vivot A., Gonzalez C., Raffaitin C., Barberger-Gateau P., Gin H., Rigalleau V.: Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. Diabete Metab. 39, 349–354 (2013)
61. Conway B.N., Aroda V.R., Maynard J.D., Matter N., Fernandez S., Ratner R.E., Orchard T.J.: Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care. 34, 1000–1005 (2011)
62. Conway B.N., Aroda V.R., Maynard J.D., Matter N., Fernandez S., Ratner R.E., Orchard T.J.: Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care. 35, 2331–2336 (2012)
63. Orchard T.J., Lyons T.J., Cleary P.A., Braffett B.H., Maynard J., Cowie C., Gubitosi-Klug R.A., Way J., Anderson K., Barnie A., Villavicencio S.: DCCT/EDIC research group: the association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care. 36, 3146–3153 (2013)
64. Sveen K.A., Nerdrum T., Hanssen K.F., Brekke M., Torjesen P.A., Strauch C.M., Sell D.R., Monnier V.M., Dahl-Jorgensen K., Steine K.: Impaired left ventricular function and myocardial blood flow reserve in patients with long-term type 1 diabetes and no significant coronary artery disease: associations with protein glycation. Diab Vasc. Dis. Res. 11, 84–91 (2014)
65. Campbell D.J., Somaratne J.B., Jenkins A.J., Prior D.L., Yii M., Kenny J.F., Newcomb A.E., Schalkwijk C.G., Black M.J., Kelly D.J.: Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels. PLoS One. 7, e49813 (2012)
66. Ueno H., Koyama H., Tanaka S., Fukumoto S., Shinohara K., Shoji T., Emoto M., Tahara H., Kakiya R., Tabata T., Miyata T., Nishizawa Y.: Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism. 57, 1452–1457 (2008)
67. Watfa G., Soulis G., Tartagni E., Kearney-Schwartz A., Borghi C., Salvi P., Benetos A.: Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations. Diabete Metab. 38, 413–419 (2012)
68. De Groot L., Jager N.A., Westra J., Smit A.J., Kallenberg C.G., Posthumus M.D., Bijl M.: Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? Rheumatology (Oxford). 54, 1257–1261 (2015)
69. Llaurado G., Ceperuelo-Mallafre V., Vilardell C., Simo R., Gil P., Cano A., Vendrell J., Gonzalez-Clemente J.M.: Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. J. Endocrinol. 221, 405–413 (2014)
70. De Boer, S.A., Fokkens, B.T., Lefrandt, J.D., Glaudemans, A.W.J.M., Slart, R.H.J.A., Smit, A.J., et al.: Skin AGE are associated with arterial calcification but not to arterial inflammation in recently diagnosed type 2 diabetes patients. Abstract presented at the 12th International Symposium on the Maillard Reaction, 4 September 2015, Tokyo, Japan
71. Araszkiewicz A., Soska J., Borucka K., Olszewska M., Niedzwiecki P., Wierusz-Wysocka B., Zozulinska-Ziolkiewicz D.: In diabetic Charcot neuroarthropathy impaired microvascular function is related to long lasting metabolic control and low grade inflammatory process. Microvasc. Res. 101, 143–147 (2015)
72. Ueno H., Koyama H., Fukumoto S., Tanaka S., Shoji T., Shoji T., Emoto M., Tahara H., Inaba M., Kakiya R., Tabata T., Miyata T., Nishizawa Y.: Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism. 60, 453–459 (2011)
73. Lutgers H.L., Graaff R., de Vries R., Smit A.J., Dullaart R.P.: Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur. J. Clin. Investig. 40, 812–817 (2010)
74. Mulder D.J., van Haelst P.L., Gross S., de Leeuw K., Bijzet J., Graaff R., Gans R.O., Zijlstra F., Smit A.J.: Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis. 197, 217–223 (2008)
75. den Dekker M.A., Zwiers M., van den Heuvel E.R., de Vos L.C., Smit A.J., Zeebregts C.J., Oudkerk M., Vliegenthart R., Lefrandt J.D., Mulder D.J.: Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis. PLoS One. 8, e83084 (2013)
76. Brodeur M.R., Bouvet C., Bouchard S., Moreau S., Leblond J., Deblois D., Moreau P.: Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes. PLoS One. 9, e85922 (2014)
77. Barnes D.E., Yaffe K.: The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 10, 819–828 (2011)
78. Roy T., Lloyd C.E.: Epidemiology of depression and diabetes: a systematic review. J. Affect. Disord. 142(Suppl), S8–21 (2012)
79. Spauwen P.J., van Eupen M.G., Kohler S., Stehouwer C.D., Verhey F.R., van der Kallen C.J., Sep S.J., Koster A., Schaper N.C., Dagnelie P.C., Schalkwijk C.G., Schram M.T., van Boxtel M.P.: Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: the Maastricht study. J. Clin. Endocrinol. Metab. 100, 951–960 (2015)
80. Moran C., Munch G., Forbes J.M., Beare R., Blizzard L., Venn A.J., Phan T.G., Chen J., Srikanth V.: Type 2 diabetes, skin autofluorescence, and brain atrophy. Diabetes. 64, 279–283 (2015)
81. Van Dooren, F.E.P., Pouwer, F., Schalkwijk, C.G., Sep, S.J.S., Stehouwer, C.D.A., Henry, R.M.A., et al.: Advanced glycation end product (AGE) accumulation in the skin is associated with depression - The Maastricht Study. 2015. PhD thesis, University of Maastricht, the Netherlands
82. Daien V., Le Pape A., Heve D., Carriere I., Villain M.: Incidence, risk factors, and impact of age on retinal detachment after cataract surgery in France: a National Population Study. Ophthalmology. 122, 2179–2185 (2015)
83. Fokkens, B.T., Los, L.I., Hooymans, J.M.M., Smit, A.J.: Skin autofluorescence and vitreous pentosidine in proliferative vitreous retinopathy. Abstract presented at the 11th International Symposium on the Maillard Reaction, 18 September 2012, Nancy, France
84. Schram M.T., Sep S.J., van der Kallen C.J., Dagnelie P.C., Koster A., Schaper N., Henry R.M., Stehouwer C.D.: The Maastricht study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. Eur. J. Epidemiol. 29, 439–451 (2014)
85. Scholtens S., Smidt N., Swertz M.A., Bakker S.J., Dotinga A., Vonk J.M., van Dijk F., van Zon S.K., Wijmenga C., Wolffenbuttel B.H., Stolk R.P.: Cohort profile: LifeLines, a three-generation cohort study and biobank. Int. J. Epidemiol. 44, 1172–1180 (2015)
86. McIntyre N.J., Fluck R.J., McIntyre C.W., Taal M.W.: Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin. J. Am. Soc. Nephrol. 6, 2356–2363 (2011)
87. Crowley L.E., Johnson C.P., McIntyre N., Fluck R.J., McIntyre C.W., Taal M.W., Leung J.C.: Tissue advanced glycation end product deposition after kidney transplantation. Nephron Clin. Pract. 124, 54–59 (2013)
88. Fraser S.D., Roderick P.J., McIntyre N.J., Harris S., McIntyre C.W., Fluck R.J., Taal M.W.: Skin autofluorescence and all-cause mortality in stage 3 CKD. Clin. J. Am. Soc. Nephrol. 9, 1361–1368 (2014)